抗体介导的心脏移植排斥反应诊治进展  

Progress in diagnosis and treatment of antibody mediated heart transplantation rejection

作　　者：黄慧敏 刘佳[1] 刘凯轩 盛开[2] Huang Huimin;Liu Jia;Liu Kaixuan;Sheng Kai(Second School of Clinical Medicine,Lanzhou University,Lanzhou 73000,China;Deparment of Cardiovascular Surgry ICU,The Second Hospital,Lanzhou University,Lanzhou 730000,China)

机构地区：[1]兰州大学第二临床医学院,兰州730000 [2]兰州大学第二医院心脏外科ICU,兰州730000

出　　处：《中华胸心血管外科杂志》2024年第5期316-320,共5页Chinese Journal of Thoracic and Cardiovascular Surgery

基　　金：兰州大学第二医院萃英学子科研培育计划(CYXZ2023-XX)。

摘　　要：抗体介导排斥反应(antibody-mediated rejection,AMR)是一种具有特征血清学、组织病理学、免疫病理学、分子病理学的临床情况,临床异质性明显,诊断标准各异,已有的大型随机临床试验对AMR治疗的评估尚未统一。本文综述AMR的诊治进展,为改善心脏移植总体预后提供参考。AMR is a clinical situation with characteristic serology,histopathology,immunopathology,and molecular pathology.Clinical heterogeneity is significant,and diagnostic criteria vary.There have been large-scale randomized clinical trials evaluating AMR treatment,but there is still no consensus.This article provides a review of its diagnosis and treatment progress,providing clues for improving the overall prognosis of heart transplantation.

关 键 词：随机临床试验 抗体介导 诊断标准 免疫病理学 分子病理学 心脏移植 组织病理学 诊治进展 

分 类 号：R654.2[医药卫生—外科学]